FDA Confirms Sinopharm Submits Application For Emergency Use Of COVID-19 Vaccines In PH

The FDA confirmed that Sinopharm had submitted an application for emergency use of its COVID-19 vaccines in the Philippines.

The Food and Drug Administration (FDA) on Tuesday confirmed that China’s Sinopharm had submitted an application for emergency use of its COVID-19 vaccines in the Philippines.

This, after Presidential Spokesperson Harry Roque on Monday said that Chinese vaccine manufacturer Sinopharm had already submitted its application for the emergency use of its COVID-19 vaccines in the country.

FDA Sinopharm emergency use

CNN Philippines reported that the Food And Drug Administration confirmed receipt of an application from China’s Sinopharm with regards to its COVID-19 vaccine’s emergency use in the Philippines.

In an interview on “The Source”, FDA Director-General Eric Domingo told CNN Philippines that a representative of Sinopharm filed an online application for emergency use authorization (EUA), but noted that the attached documents were still being reviewed.

I did have my staff check it now… And then online, yesterday afternoon, an applicant did send an application for EUA for Sinopharm. So meron ngang dumating daw kahapon. So they’re looking at the documents now to see kung (if) complete or if there are any documents that need to be submitted before we officially accept the application,” Domingo said.

Domingo’s statement came after Presidential spokesperson Harry Roque on Monday revealed that China’s Sinopharm sent an application for emergency use authorization in the Philippines.

READ ALSO | Palace: Sinopharm Submits Application For Emergency Use Of COVID-19 Vaccines In PH

Earlier, Domingo said the evaluation on Sinopharm’s COVID-19 vaccine may take a longer period of time since it had not received an emergency use authorization from any stringent regulatory body.

Meanwhile, Domingo said that the emergency use authorization application of Russia’s Gamaleya Research Institute also remained “pending”, with the regulatory body still waiting for additional documents for Gamaleya Institute’s Sputnik V COVID-19 vaccine.

For more news and updates, you may feel free to visit this site more often. You may also visit Newspapers.ph via our official Facebook page and YouTube channel.

Leave a Comment